Ascendis Pharma initiates clinical trial of dwarfism drug

Danish biotech company Ascendis Pharma’s achondroplasia treatment, Transcon CNP, will be clinically tested across six sites in China.

Photo: Kevin Grønnemann

Ascendis Pharma has initiated a hunt for new patients for a phase II trial in China, according to the Clinical Trials database.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs